Darzalex (daratumumab) / Genmab, J&J  >>  Phase 2
Welcome,         Profile    Billing    Logout  

168 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Darzalex (daratumumab) / J&J
STORM, NCT02336815 / 2016-003094-18: Selinexor Treatment of Refractory Myeloma

Hourglass Sep 2023 - Sep 2023 : Presentation of data from STORM trial for r/r multiple myeloma at IMS 2023
Checkmark Data from STORM trial in combination with dexamethasone for multiple myeloma
Aug 2020 - Aug 2020: Data from STORM trial in combination with dexamethasone for multiple myeloma
Checkmark Data from STORM trial at ASH 2018
Dec 2018 - Dec 2018: Data from STORM trial at ASH 2018
More
Completed
2b
202
Europe, US
Selinexor, KPT-330, Dexamethasone
Karyopharm Therapeutics Inc
Multiple Myeloma
07/19
07/19
DARA-GEN501, NCT00574288 / 2007-003783-22: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma

Checkmark From GEN501 and SIRIUS trials for MM at ASH 2017 [screenshot]
Dec 2017 - Dec 2017: From GEN501 and SIRIUS trials for MM at ASH 2017 [screenshot]
Checkmark From SIRIUS and GEN501 trials in multiple myeloma at EHA 2016
Jul 2016 - Jul 2016: From SIRIUS and GEN501 trials in multiple myeloma at EHA 2016
Checkmark MM
More
Completed
2
104
US, Europe
Part 1: Daratumumab, HuMax-CD38, Part 2: Daratumumab, Methylprednisolone, Dexamethasone
Janssen Research & Development, LLC
Multiple Myeloma
01/15
04/17
Sirius, NCT01985126 / 2013-000752-18: An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Checkmark From GEN501 and SIRIUS trials for MM at ASH 2017 [screenshot]
Dec 2017 - Dec 2017: From GEN501 and SIRIUS trials for MM at ASH 2017 [screenshot]
Checkmark From SIRIUS and GEN501 trials in multiple myeloma at EHA 2016
Jul 2016 - Jul 2016: From SIRIUS and GEN501 trials in multiple myeloma at EHA 2016
Checkmark EHA 2016
More
Completed
2
124
US, Canada, Europe
Daratumumab 16 mg/kg (Part 1), Daratumumab 8 mg/kg (Part 1), Methylprednisolone, Acetaminophen, Diphenhydramine, Daratumumab (Part 2)
Janssen Research & Development, LLC
Multiple Myeloma
01/15
05/17
2016-000287-42: Amyloidosis Patients traitment

Completed
2
40
Europe
HuMax-CD38, NA, Concentrate for solution for infusion
CHU de Limoges, CHU DE LIMOGES, JANSSEN, Societ¿ italiana per l'amiloidosi
AL Amyloidosis, Amyloidosis, Body processes [G] - Biological Phenomena [G16]
 
 
NCT02413489 / 2014-005299-26: An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

Terminated
2
36
US, Europe, RoW
Daratumumab
Janssen Research & Development, LLC
Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
06/17
06/17
2016-002600-90: Treatment of unfit and frail newly diagnosed multiple myeloma patients with ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in . How effective is this treatment and how well is it tolerated? Behandeling van kwetsbare of niet fitte patiënten met nieuw gediagnostiseerd Multipel Myeloom met ixazomib, daratumumab en lage dosis dexamethason, gevolgd door een onderhoudsbehandeling met ixazomib en daratumumab voor maximaal 2 jaar. Wat is het effect van deze behandeling op de ziekte en wordt de behandeling goed verdragen?

Ongoing
2
132
Europe
Ixazomib citrate, daratumumab, Capsule, Concentrate for solution for infusion, Ninlaro 4 mg, DARZALEX, Ninlaro 3 mg, Ninlaro 2.3 mg
HOVON Foundation, Dutch Cancer Society, Janssen, Takeda Oncology
Multiple Myeloma, Multiple myeloma, Diseases [C] - Cancer [C04]
 
 
NCT02944565: Daratumumab in Treating Patients With Multiple Myeloma

Completed
2
28
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414
Ohio State University Comprehensive Cancer Center
Plasma Cell Myeloma
07/17
07/17
FUSION-MM-005, NCT03000452 / 2016-003801-32: A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Completed
2
18
US, Europe
DARATUMUMAB, DARA, DURVALUMAB, MEDI4736; DURVA
Celgene
Multiple Myeloma
09/17
12/17
2017-003951-44: Study to evaluate Effects of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and /or Refractory Multiple Myeloma who Have Received at least 2 Prior Lines of Therapy including Lenalidomide and a Proteasome Inhibitor

Ongoing
2
57
Europe
Daratumumab, Concentrate for solution for infusion, DARZALEX
Hellenic Society of Hematology, Janssen Pharmaceutica NV
Relapsed and /or Refractory Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
CR108235, NCT02951819: A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma

Checkmark From LYRA study for relapsed MM at ASH 2017 [screenshot]
Dec 2017 - Dec 2017: From LYRA study for relapsed MM at ASH 2017 [screenshot]
Completed
2
101
US
Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone
Janssen Scientific Affairs, LLC
Multiple Myeloma
03/18
08/20
2017-002326-21: Clinical Trial with selinexor (KPT-330), bortezomib and low-dose dexamethasone plus daratumumab (SELIBORDARA) for the treatment of patients with refractory or relapsed and refractory multiple myeloma Ensayo clínico de selinexor (KPT-330), bortezomib y dosis baja de dexametasona más daratumumab (SELIBORDARA) para el tratamiento de pacientes con mieloma múltiple en recaída y/o refractario

Ongoing
2
62
Europe
DARZALEX, VELCADE, Selinexor, Infusion, Solution for injection, Tablet, DARZALEX, VELCADE
Fundación PETHEMA, Fundación Pethema
Patients with refractory or relapsed and refractory multiple myeloma Pacientes con mieloma múltiple en recaída y/o refractario, patients with multiple myeloma Pacientes con mieloma múltiple, Diseases [C] - Cancer [C04]
 
 
2018-000386-36: A Pilot study on the efficacy of Daratumumab in Multiple Myeloma (MM) patients in >VGPR/MRD-positive by next generation flow STUDIO PILOTA SULL’EFFICACIA DI DARATUMUMAB IN PAZIENTI AFFETTI DA MIELOMA MULTIPLO IN RISPOSTA MOLTO BUONA/MALATTIA MINIMA RESIDUA POSITIVE (>VGPR/MRD-POSITIVI) VALUTATA TRAMITE CITOFLUORIMETRIA A FLUSSO DI NUOVA GENERAZIONE

Not yet recruiting
2
50
Europe
Darzalex, [JNJ-54767414], Concentrate for solution for infusion, DARZALEX - 20 MG/ML- CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO)- 20 ML- 1 FLACONCINO, DARZALEX - 20 MG/ML- CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO)- 5 ML- 1 FLACONCINO
AZIENDA OSPEDALIERA UNIVERSITARIA SENESE, Janssen Cilag Spa
Multiple Myeloma MIELOMA MULTIPLO, Multiple Myeloma MIELOMA MULTIPLO, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT03011034 / 2016-003328-22: Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Completed
2
34
Europe, US, RoW
Talacotuzumab, JNJ-56022473, Daratumumab, JNJ-54767414
Janssen Research & Development, LLC
Myelodysplastic Syndromes
01/19
10/21
GRIFFIN , NCT02874742: Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

Checkmark Data from GRIFFIN trial for multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Data from GRIFFIN trial for multiple myeloma at ASH 2022
Checkmark Data from GRIFFIN trial for multiple myeloma at ASH 2021
Dec 2021 - Dec 2021: Data from GRIFFIN trial for multiple myeloma at ASH 2021
Checkmark Data from GRIFFIN trial for multiple myeloma at ASH 2020
More
Completed
2
224
US
Lenalidomide, Bortezomib, Dexamethasone, Daratumumab
Janssen Research & Development, LLC
Multiple Myeloma
01/19
04/22
NCT03035357: Neoadjuvant Listeria or Daratumumab in Prostate Cancer

Withdrawn
2
0
NA
Daratumumab
M.D. Anderson Cancer Center, Janssen-Cilag div. of Johnson&Johnson SE
Malignant Neoplasms of Male Genital Organs, Prostate Cancer
03/19
03/19
KEYNOTE-668, NCT03221634: Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/)

Withdrawn
2
0
Canada, US, Europe, RoW
Pembrolizumab, MK-3475, Daratumumab, DARZALEX®
Merck Sharp & Dohme LLC
Multiple Myeloma
03/19
06/21
2018-002090-21: Daratumumab, pomalidomide and dexamethasone for del(17p) positive relapsed and relapsed/refractory multiple myeloma patients [DEDALO] Daratumumab, pomalidomide e desametasone per pazienti affetti da mieloma multiplo recidivato e/o refrattario positivi per del(17p) [DEDALO].

Not yet recruiting
2
45
Europe
Daratumumab, Pomalidomide, Desametasone, Desametasone IV, [NA], Concentrate for solution for infusion, Capsule, hard, Oral drops, solution, Solution for injection, IMNOVID - 4 MG - CAPSULA RIGIDA - USO ORALE - BLISTER (PVC/PCTFE) - 21 CAPSULE, SOLDESAM - 0.2% GOCCE ORALI, SOLUZIONE FLACONE 10 ML, SOLDESAM - 8 MG/2 ML SOLUZIONE INIETTABILE 3 FIALE 2 ML
Fondazione EMN Italy Onlus, Janssen Pharmaceutica NV, Celgene International II
Multiple Myeloma patients with relapsed or relapsed/refractory disease with the presence of del(17p) in the plasma cell clone Mieloma Multiplo recidivato o recidivato/refrattario con del(17p) nel clone delle plasmacellule, Multiple Myeloma patients with relapsed or relapsed/refractory disease Mieloma Multiplo recidivato o recidivato/refrattario, Diseases [C] - Cancer [C04]
 
 
REBUILD, NCT03475628: Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma

Unknown status
2
57
Europe
Daratumumab
Hellenic Society of Hematology, Janssen Pharmaceuticals
Multiple Myeloma
06/19
02/20
AMN004, NCT03143036: Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma

Unknown status
2
100
RoW
Daratumumab, thalidomide and dexamethasone
National University Hospital, Singapore, Janssen, LP, International Myeloma Foundation
Relapse and / or Refractory Myeloma
07/19
07/22
AMYDARA, NCT02816476: Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis

Completed
2
40
Europe
Daratumumab
University Hospital, Limoges
Amyloidosis
10/19
10/20
NCT03095118: Daratumumab in Treatment of PGNMID and C3 GN

Completed
2
12
US
Daratumumab, Darzalex
Fernando Fervenza
Membranoproliferative Glomerulonephritis
10/19
05/20
ACTRN12617000202369: A randomized phase 2 study of bortezomib, cyclophosphamide and dexamethasone induction (VCD) compared with VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant ineligible patients with multiple myeloma.

Completed
2
120
 
Alfred Health, Janssen Pharmaceuticals
Multiple Myeloma
 
 
Dara_DCEP, NCT04065308: Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma

Checkmark Data from Dara_DCEP study in combination with chemotherapy for R/R multiple myeloma
Nov 2022 - Nov 2022: Data from Dara_DCEP study in combination with chemotherapy for R/R multiple myeloma
Unknown status
2
33
RoW
Drug Combinations, Daratumumab plus DCEP
Seoul National University Hospital
Multiple Myeloma in Relapse, Plasmacytoma, Daratumumab
12/19
09/21
NCT02927925: A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type

Completed
2
32
RoW
Daratumumab
Janssen Research & Development, LLC
Lymphoma
01/20
01/20
IFM2014-04, NCT02626481 / 2015-002221-19: Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma

Completed
2
64
Europe
Daratumumab, Experimental Arm, Dexamethasone
University Hospital, Lille, Janssen, LP, Intergroupe Francophone du Myelome
Multiple Myeloma
03/20
03/20
2018-002644-91: Clinical trial with Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin in patients with relapsed/refractory CD38 positive peripheral T-cell lymphoma Sperimentazione clinica con Daratumumab in combinazione con gemcitabina, desametasone e cisplatino per il trattamento di pazienti con linfoma a cellule T periferico CD38 positivo ricaduto/refrattario

Not yet recruiting
2
35
Europe
Darzalex, Desametasone, Gemcitabina, Cisplatino, [IMP1], [IMP2], [IMP4], [IMP3], [IMP5], Concentrate for solution for infusion, Concentrate for solution for injection, DARZALEX - 20 MG/ML- CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO)- 20 ML- 1 FLACONCINO, DARZALEX - 20 MG/ML- CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO)- 5 ML- 1 FLACONCINO, DECADRON - 4 MG/1 ML SOLUZIONE INIETTABILE 3 FIALE DA 1 ML, GEMCITABINA ACCORD - 100 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 10 ML, CISPLATINO ACCORD HEALTHCARE ITALIA - 1MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 10 ML
FONDAZIONE ITALIANA LINFOMI ONLUS, Janssen
Relapsed/refractory CD38 positive peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of TFH cell origin Linfoma a cellule T periferico CD38 positivo ricaduto/refrattario di tipo non ulteriormente specificato (PTCL-NOS), angioimmunoblastico (AITL) e con fenotipo T-follicular helper (TFH), Relapsed/refractory CD38 positive peripheral T-cell lymphoma Linfoma a cellule T periferico CD38 positivo ricaduto/refrattario, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2019-001645-41: Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study

Not yet recruiting
2
462
Europe
Darzalex, Bortezomib, Dexamethasone, HUMaX-CD38, L01XX32, Dexamethasone, Capsule, hard, Powder for solution for infusion, Concentrate for solution for infusion, Powder for solution for injection, Tablet, Revlimid, Kyprolis, Darzalex, Velcade, Dexamethasone
Memorial Sloan Kettering Cancer center, Amgen
Newly diagnosed Multiple Myeloma Multipelt Myelom, Multiple Myeloma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT03207542: Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Withdrawn
2
0
NA
Daratumumab
M.D. Anderson Cancer Center, Janssen Scientific Affairs, LLC
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
07/20
07/21
NCT03697629: A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma

Completed
2
40
Canada
Daratumumab, Darzalex
Canadian Myeloma Research Group
Multiple Myeloma in Relapse
07/20
12/21
ACTRN12618001490268: Daratumumab-lenalidomide-dexamethasone (DRd) salvage for newly diagnosed Multiple Myeloma patients who fail bortezomib induction therapy

Active, not recruiting
2
50
 
Australiasian Leukaemia and Lymphoma Group, Celgene, Janssen-Cilag
Newly-diagnosed multiple myeloma
 
 
PREDATOR, NCT03697655 / 2017-003253-41: Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma

Recruiting
2
274
Europe
Daratumumab 20 MG/ML [Darzalex], Darzalex
Polish Myeloma Consortium, Janssen-Cilag Ltd., Bioscience, S.A.
Multiple Myeloma
09/20
07/24
NCT03679624: Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

Terminated
2
1
US
Ibrutinib, IMBRUVICA, Daratumumab, DARZALEX
Weill Medical College of Cornell University, Janssen Scientific Affairs, LLC, Mayo Clinic
Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia of Lymph Nodes, Waldenstrom's Macroglobulinaemia, Without Mention of Remission, Waldenstrom's Macroglobulinemia Refractory
09/20
10/20
2019-003856-35: Study to test effectiveness and safety of Daratumumab for first line treatment in patients with transplant-ineligible myeloma Studie zur Bewertung der Wirksamkeit und Sicherheit des Medikaments Daratumab bei Patienten mit unbehandeltem Multiplem Myelom (MM)

Not yet recruiting
2
160
Europe
DARZALEX, Solution for injection, Darzalex®
University of Cologne, Janssen Cilag
multiple myeloma (untreated), Untreated patients with multiple myeloma, Diseases [C] - Cancer [C04]
 
 
2019-001962-13: Daratumumab and Pomalidomide in previously treated patients with AL amyloidosis Daratumumab e Pomalidomide in pazienti con amiloidosi AL già trattati

Not yet recruiting
2
40
Europe
Pomalidomide, Daratumumab, [Pomalidomide], [Daratumumab], Capsule, hard, Concentrate for solution for injection, Imnovid
FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO, AIFA - Italian Medicines Agency
AL amyloidosis Amiloidosi AL, AL amyloidosis Amiloidosi AL, Diseases [C] - Immune System Diseases [C20]
 
 
NCT03187262: A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

Completed
2
13
US
Daratumumab, Darzalex
Dana-Farber Cancer Institute, Janssen, LP
Waldenström Macroglobulinemia
01/21
12/21
NCT04467281: A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma

Withdrawn
2
0
NA
89Zr-DFO-daratumumab, PET/CT
Memorial Sloan Kettering Cancer Center
Multiple Myeloma
02/21
02/21
2017-003950-18: Efficacy of Daratumumab in Patients with Relapsed/Refractory Myeloma with Renal Impairment

Completed
2
38
Europe
Daratumumab, Daratumumab, Concentrate for solution for infusion, DARZALEX
Hellenic Society of Hematology, HELLENIC SOCIETY OF HEMATOLOGY, Janssen Pharmaceutica NV
Relapsed and /or Refractory Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
Dare Study, NCT03450057 / 2017-003950-18: Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment

Completed
2
38
Europe
Daratumumab with dexamethasone, DaraD, Darzalex, Dara, Dex
Hellenic Society of Hematology, Janssen Pharmaceuticals
Relapsed/Refractory Multiple Myeloma
03/21
03/21
2019-004170-26: PRIMARY PLASMA CELL LEUKEMIA: A STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION PCL-2 Study

Not yet recruiting
2
29
Europe
Daratumumab, Lenalidomide, BORTEZOMIB SC, DEXAMETHASONE IV, DEXAMETHASONE PO, JNJ-54767414, CC-5013 / CDC-501, Solution for injection, Capsule, hard, Powder for solution for injection, Tablet, Darzalex 1800 mg, Revlimid 5mg gélules, Revlimid 10 mg gélules
Assistance-Publique - Hôpitaux de Paris, Ministère de la Santé
PRIMARY PLASMA CELL LEUKEMIA, PRIMARY PLASMA CELL LEUKEMIA, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT04205240: Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

Terminated
2
1
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Fludarabine, Fluradosa, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Mycophenolate Mofetil, Cellcept, MMF, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
Srinivas Devarakonda
Recurrent Plasma Cell Myeloma
05/21
11/21
2020-003092-18: Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma inducedacute renal failure requiring dialysis - “Time Is Kidney in the Treatment of myelomA Cast nephropathy”

Ongoing
2
50
Europe
Solution for injection, Powder for solution for infusion, Capsule, hard, Tablet, DARZALEX, Kyprolis, Imnovid, Fortecortin
Medical University Innsbruck, AMGEN GmbH, Calgene GmbH, Janssen GmbH
Multiple Myeloma: Patients with MM are frequently diagnosed primarily due to renal failure. Up to 40% of the myeloma patients present with renal failure at diagnosis and approximately 10% require dialysis., Multiple Myeloma: Patients with MM are frequently diagnosed primarily due to renal failure. Up to 40% of the myeloma patients present with renal failure at diagnosis and app. 10% require dialysis., Diseases [C] - Cancer [C04]
 
 
GMMG-DANTE, NCT02977494 / 2016-000433-51: Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment

Completed
2
22
Europe
Daratumumab, Darzalex, Bortezomib, Velcade, Dexamethasone, Fortecortin
Universitätsklinikum Hamburg-Eppendorf
Multiple Myeloma
06/21
06/21
2021-000962-14: A drug trial to evaluate the safety and efficacy of daratumumab, an agent already approved for other diseases, in combination with standard background anti-rheumatic therapy in patients with moderate-to-severe systemic lupus erythematosus Eine Medikamentenstudie zur Untersuchung der Sicherheit und Wirksamkeit des bereits für andere Erkrankungen zugelassenen Wirkstoffs Daratumumab in Kombination mit einer anti-rheumatischen Standard-Begleittherapie bei Patienten mit mittelschwerem bis schwerem systemischen Lupus erythematodes

Not yet recruiting
2
10
Europe
Daratumumab, JNJ-54767414, Solution for injection, Darzalex
Charité - Universitätsmedizin Berlin, JANSSEN-CILAG GmbH
Systemic Lupus Erythematosus Systemischer Lupus Erythematodes (SLE), Systemic Lupus Erythematosus Systemischer Lupus Erythematodes (SLE), Diseases [C] - Immune System Diseases [C20]
 
 
2021-001990-22: An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination with DaratUMumab followed by Maintenance with Daratumumab in the Frontline Setting of Primary Plasma CEll LEukemIA: A Trial of the Greek Myeloma Study Group

Ongoing
2
43
Europe
Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), Bortezomib 3,5 mg, Cyclophosphamide 50mg, Dexaton 2mg/5ml, Doxorubicin 10mg/5ml, Doxorubicin 50mg/25ml, JnJ 54767414, Solution for injection, Powder for solution for injection, Tablet, Oral solution, Concentrate for solution for infusion, Darzalex 1.800mg, Velcade 3,5mg, ENDOXAN C. TAB 50mg/TAB, DEXATON oral sol. 2mg/5ml BT X 1 BOTTLE X 150 ml, ADRIBLASTINA 10mg/5ml, ADRIBLASTINA 50mg/25ml
Hellenic Society of Haematology (HSH), Janssen Cilag
Primary plasma cell leukemia Πρωτοπαθή Πλασματοκυτταρική Λευχαιμία, Primary plasma cell leukemia, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
KyDaR, NCT04065789: Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients

Completed
2
41
RoW
Carfilzomib, Kyprolis, Daratumumab, Darzalex, Lenalidomide, Revlimid, Dexamethasone
Tel-Aviv Sourasky Medical Center
Myeloma Multiple, Myeloma, Plasma-Cell, Myeloma-Multiple, Plasma Cell Myeloma
08/21
11/21
AMN006, NCT03695744: Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma

Active, not recruiting
2
27
RoW
Daratumumab, Bortezomib, Dexamethasone
Singapore General Hospital, International Myeloma Foundation, Janssen, LP
Multiple Myeloma, Myeloma
09/21
04/24
2020-004349-35: Melflufen with dexamethasone and continued daratumumab in patients with multiple myeloma Melflufen-dexamethason med fortsat daratumumab i daratumumab-ufølsom myelomatose

Not yet recruiting
2
50
Europe
Melflufen, Daratumumab, Dexamethasone, Powder for solution for infusion, Concentrate for solution for infusion, Solution for injection, Tablet, Darzalex, Dexamethasone
Klinisk Forskningsenhed, Medicinsk Afdeling, Hæmatologisk Afsnit, Sygehus Lillebælt, Vejle Sygehus, Oncopeptides AB
Multiple Myeloma, Multiple Myeloma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
DARIA, NCT03746652 / 2018-002282-19: Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Unknown status
2
50
Europe
Daratumumab, Ixazomib, Dexamethasone
Hellenic Society of Hematology, Janssen Pharmaceutica NV, Takeda
Multiple Myeloma
12/21
12/21
NCT04251065: Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Active, not recruiting
2
8
Europe
Daratumumab, Darzalex
Fondazione Italiana Linfomi ONLUS
Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma
12/21
11/22
NCT03439293 / 2017-003977-32: A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Completed
2
61
Europe, US, RoW
Ixazomib, NINLARO, Daratumumab, Dexamethasone
Takeda
Multiple Myeloma
01/22
06/23
FUSIONMM-003, NCT02807454 / 2016-001209-17: A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

Terminated
2
37
Europe, Canada, US
Daratumumab, Durvalumab, Pomalidomide, Dexamethasone
Celgene
Multiple Myeloma
01/22
01/22
2021-001798-21: A Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Not yet recruiting
2
153
RoW
Magrolimab, Daratumumab, Dexamethasone, Pomalidomide, Bortezomib, carfilzomib, GS-4721, Concentrate for solution for infusion, Solution for infusion, Tablet, Capsule, hard, Powder for solution for injection, Powder for solution for infusion, Solution for injection
Gilead Sciences, Inc., Gilead Sciences, Inc.
Relapsed/Refractory Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
2021-005856-12: Monoclonal gammopathies of renal significance (MGRS) in Finland

Not yet recruiting
2
35
Europe
Injection, Darzalex, daratumumab
Helsinki University Central Hospital, Janssen-Cilag
Rare renal diseases linked to monoclonal gammopathy, Rare renal diseases linked to monoclonal gammopathy, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
IFM 2018-04, NCT03606577: An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

Active, not recruiting
2
50
Europe
Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone
Nantes University Hospital
Multiple Myeloma
02/22
11/27
NCT03841565: Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Withdrawn
2
0
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Pomalidomide, 4-Aminothalidomide, Actimid, CC-4047, Imnovid, Pomalyst
Academic and Community Cancer Research United, Janssen Scientific Affairs, LLC, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma
02/22
02/22
2022-000281-18: Treatment with daratumumab injections in moderate to severe ME/CFS

Not yet recruiting
2
10
Europe
Solution for injection, Darzalex
Haukeland University Hospital, Dept. of Oncology and Medical Physics, The Kavli Trust, ME-nettverket i Norge (MENiN), MEandYou, Fokus på ME, The Norwegian ME Association, The legacy of Thorstein Hereid
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, ME/CFS, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-000382-16: Efficacy of daratumumab (Dara) retreatment of relapsed/ refractory multiple myeloma (RRMM) patients in combination with panobinostat, bortezomib-and dexamethasone Wirksamkeit einer wiederholten Daratumumab (Dara) Behandlung von Patienten mit rezidiviertem/refraktärem Multiplen Myelom (RRMM) in Kombination mit Panobinostat, Bortezomib und Dexamethason

Not yet recruiting
2
30
Europe
Darzalex, Farydak, Velcade, L01XC24, L01XX42, L01XX32, Concentrate for solution for injection, Capsule, hard, Powder for solution for injection, Daratumumab (DARZALEX® 1.800 mg Injektionslösung), Farydak (Panobinostat), Velcade (Bortezomib)
Medical Center - University of Freiburg, University of Freiburg, Faculty of Medicine, Janssen-Cilag GmbH
Relapsed and refractory multiple myeloma Rezidives und refraktäres Multiples Myelom, Relapsed and refractory multiple myeloma wiederkehrendes / therapieresistentes Multiples Myelom, Diseases [C] - Cancer [C04]
 
 
2021-002190-25: National study to evaluate Iberdomide-dexamethasone alone or in combination with standard multiple myeloma treatment in transplant ineligible newly diagnosed patients. Estudio nacional para evaluar Iberdomida-dexametasona sola o en combinación con el tratamiento estándar del mieloma múltiple en pacientes de diagnóstico reciente no elegibles para trasplante

Not yet recruiting
2
1
Europe
IBERDOMIDE, Dexamethasone, CC-220, Capsule, hard, Solution for injection, Tablet, DARZALEX 1.800 MG SOLUCION INYECTABLE
Fundacion PETHEMA, Bristol Myers Squibb Company, Janssen-Cilag, SA
Multiple Myeloma Mieloma Multiple, Multiple Myeloma Mieloma Multiple, Diseases [C] - Cancer [C04]
 
 
DART4MM, NCT03992170: Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive

Recruiting
2
50
Europe
Daratumumab, Darzalex
Azienda Ospedaliera Universitaria Senese, Janssen-Cilag S.p.A.
Myeloma Multiple
06/22
12/22
2021-002639-48: A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis

Not yet recruiting
2
150
Europe
Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), JNJ-54767414, Solution for injection, DAZARLEX
Janssen-Cilag International N.V., JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development, LLC
Amyloid Light Chain Amyloidosis, Amyloidosis, Diseases [C] - Immune System Diseases [C20]
 
 
2022-001594-31: A Phase 2 Study of Teclistamab in Combination with Daratumumab or Lenalidomide in Elderly Patients with Newly Diagnosed Multiple Myeloma Etude de phase II évaluant le Teclistamab en association au Daratumumab ou au Lénalidomide chez des patients âgés atteints de Myélome Multiple en traitement de première ligne

Not yet recruiting
2
82
Europe
TECLISTAMAB, JNJ-64007957, Solution for injection
CHU de LILLE, JANSSEN PHARMACEUTICA NV
A Phase 2 Study of Teclistamab in Combination with Daratumumab or Lenalidomide in Elderly Patients with Newly Diagnosed Multiple Myeloma Étude de phase 2 sur le téclistamab en association avec le daratumumab ou le lénalidomide chez des patients âgés atteints d'un myélome multiple récemment diagnostiqué., Multiple Myelome Myélome Multiple, Diseases [C] - Cancer [C04]
 
 
DELPHINUS, NCT03384654 / 2017-003377-34: A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed
2
47
Europe, US, RoW
Daratumumab, Vincristine, Prednisone, Doxorubicin, Peg-asparaginase, Cyclophosphamide, Cytarabine, 6-mercaptopurine, Methotrexate
Janssen Research & Development, LLC
Precursor Cell Lymphoblastic Leukemia-Lymphoma
09/22
09/22
SY-1425-201, NCT02807558 / 2017-000783-14: A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Checkmark Initial clinical data from cohorts
Dec 2018 - Dec 2018: Initial clinical data from cohorts
Checkmark Combination trial with SY-1425 in AML/MDS
Dec 2018 - Dec 2018: Combination trial with SY-1425 in AML/MDS
Completed
2
155
Europe, US
Tamibarotene, SY-1425, Azacitidine, Vidaza, Daratumumab, Darzalex
Syros Pharmaceuticals
Acute Myeloid Leukemia, Myelodysplastic Syndrome
01/23
01/23
2022-001186-12: Clinical trial for patients with newly diagnosed multiple myeloma to evaluate safety, tolerability and efficacy of teclistamab in combination with daratumumab, lenalidomide, dexamethasone with or without bortezomib as induction therapy, and maintenance therapy with teclistamab and lenalidomide after autologous stem cell transplantation. Klinische Studie für Patienten mit neu diagnostiziertem multiplem Myelom zur Untersuchung der Sicherheit, Verträglichkeit und Wirksamkeit von Teclistamab in Kombination mit Daratumumab, Lenalidomid, Dexamethason mit oder ohne Bortezomib in der Induktionstherapie, sowie in der Erhaltungstherapie mit Teclistamab und Lenalidomid nach einer autologen (körpereigenen) Stammzelltransplantation.

Not yet recruiting
2
50
Europe
JNJ-64007957, Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), JNJ-64007957, JNJ-54767414, Solution for injection, Darzalex
Ruprecht-Karls-University Heidelberg, Medical Faculity, represented by University Hospital Heidelberg, Janssen Research & Development, LLC
Newly Diagnosed Multiple Myeloma in patients eligible for stem cell transplantation Neu diagnostiziertes multiples Myelom bei Patienten, die für eine Stammzelltransplantation geeignet sind, Newly Diagnosed Multiple Myeloma in patients eligible for stem cell transplantation Neu diagnostiziertes multiples Myelom bei Patienten, die für eine Stammzelltransplantation geeignet sind, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT03067571: Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Terminated
2
7
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
11/22
11/22
MUKnineb, NCT03188172 / 2016-002670-12: MUK Nine b: OPTIMUM Treatment Protocol

Active, not recruiting
2
95
Europe
Cyclophosphamide, Bortezomib, Velcade, Lenalidomide, Revlamid, Daratumumab, Daralex, Dexamethasone, Melphalan, Filgrastim
University of Leeds, Myeloma UK, Celgene, Janssen, LP
Multiple Myeloma
10/25
05/26
NCT04223661: Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy

Withdrawn
2
0
US
Lenalidomide Pill, Dexamethasone, Daratumumab
Attaya Suvannasankha, Janssen Scientific Affairs, LLC, Indiana Institute for Medical Research
Multiple Myeloma
12/22
12/23
2022-000598-15: An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab) in the therapy of newly diagnosed high -risk multiple myeloma Estudio piloto fase 2, abierto y multicéntrico para evaluar la intervención temprana con anticuerpos biespecíficos redireccionadores de células T (teclistamab y talquetamab) en el tratamiento de primera línea de mieloma múltiple de alto riesgo de nuevo diagnóstico

Not yet recruiting
2
30
Europe
Darzalex, Velcade, Lenalidomida 25 mg, Dexamethasone, Lenalidomida 20 mg, Lenalidomida 15 mg, Lenalidomida 10 mg, Lenalidomida 5 mg, Teclistamab 30mg, Teclistamab 150mg, Talquetamab 3mg, Talquetamab 40mg, L01XC24, L01XX32, L04AX04, H02AB02, JNJ-64007957, JNJ-64407564, Solution for injection, Powder for solution for injection, Capsule, hard, Tablet, Darzalex 1.800 mg, Velcade 3.5mg, TECVAYLI
PETHEMA Foundation, Janssen
Multiple Myeloma Mieloma múltiple, Multiple Myeloma Mieloma múltiple, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
CA209-755, NCT03184194 / 2017-000169-60: Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide

Completed
2
62
Europe
nivolumab-daratumumab, Opdivo-darzalex, nivolumab-daratumumab with low-dose cyclophosphamide, Opdivo-darzalex with endoxan
Amsterdam UMC, location VUmc, Erasmus Medical Center, UMC Utrecht, Maastricht University Medical Center, Meander Medical Center, St. Antonius Hospital, Isala, Albert Schweitzer Hospital, Radboud University Medical Center, University Medical Center Groningen, Rijnstate Hospital
Myeloma
01/23
01/24
2022-001418-20: A Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma Estudio para evaluar la seguridad y la tolerabilidad de modakafusp alfa intravenoso como parte de un tratamiento combinado en pacientes adultos con mieloma múltiple

Not yet recruiting
2
144
Europe
Modakafusp Alfa, Darzalex, TAK-573, Powder for concentrate for solution for infusion, Capsule, hard, Solution for injection, Powder for solution for infusion, Zelvina 5 mg Hard Capsules, Zelvina 10 mg Hard Capsules, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Bortezomib STADA 2.5 mg/ml solution for injection, Kyprolis 30 mg powder for solution for infusion, Darzalex 1800mg solution for injection
Takeda Development Center Americas, Inc., Takeda Development Center Americas, Inc.
Multiple Myeloma Mieloma múltiple, Multiple Myeloma Mieloma múltiple, Diseases [C] - Cancer [C04]
 
 
NCT03490344: Short Course Daratumumab in Patients With Multiple Myeloma

Completed
2
10
US
Daratumumab, Lenalidomide
Memorial Sloan Kettering Cancer Center, Janssen Scientific Affairs, LLC
Multiple Myeloma
03/23
03/23
2022-004207-32: Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure NOT requiring dialysis

Not yet recruiting
2
50
Europe
Darzalex, Kyprolis, Imnovid, Fortecortin, Concentrate for solution for infusion, Powder for solution for infusion, Capsule, hard, Tablet, DARZALEX, Kyprolis, Imnovid, Fortecortin
Medical University Innsbruck, Internal Medicine V, AMGEN GmbH, Calgene GmbH, Janssen GmbH
Multiple Myeloma: Patients with MM are frequently diagnosed primarily due to renal failure. Patients with renal failure have a poor prognosis., Multiple Myeloma: Patients with MM are frequently diagnosed primarily due to renal failure. Patients with renal failure have a poor prognosis., Diseases [C] - Cancer [C04]
 
 
MASTER, NCT03224507: Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma

Completed
2
123
US
KRdD followed by auto-HCT, KRdD = Kyprolis (Carfilzomib), Revlimid (Lenalidomide), dexamethasone, Darzalex (Daratumumab), KRdD only
University of Alabama at Birmingham, Amgen, Janssen Scientific Affairs, LLC
Multiple Myeloma
05/23
06/23
NCT04474938: Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis

Active, not recruiting
2
40
RoW
Daratumumab, Bortezomib, Dexamethasone
Peking Union Medical College Hospital, Xian-Janssen Pharmaceutical Ltd.
Amyloidosis; Systemic
06/23
03/24
CENTAURUS, NCT02316106 / 2014-005139-14: A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

Checkmark Data from CENTAURUS study at EHA 2018
May 2018 - May 2018: Data from CENTAURUS study at EHA 2018
Checkmark From CENTAURUS trial for smoldering multiple myeloma at ASH 2017 [screenshot]
Dec 2017 - Dec 2017: From CENTAURUS trial for smoldering multiple myeloma at ASH 2017 [screenshot]
Completed
2
123
Europe, Canada, US, RoW
daratumumab
Janssen Research & Development, LLC
Multiple Myeloma
06/23
06/24
NCT04113018: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Active, not recruiting
2
39
US
Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
Wake Forest University Health Sciences, Amgen, Celgene, Janssen, LP
Multiple Myeloma
06/23
10/27
GEM-SELIBORDARA, NCT03589222: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Recruiting
2
62
Europe
Selinexor, Daratumumab, Bortezomib, Dexamethasone
PETHEMA Foundation
Refractory Multiple Myeloma
08/23
08/23
NCT03004287: 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Active, not recruiting
2
50
US
Carfilzomib, Kyprolis, Thalidomide, Thalomid, Dexamethasone, Baycadron, Daratumumab, Darzalex, Cisplatin, Platinol, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan, Etoposide, Eposin, Melphalan, ASCT, Lenalidomide, Revlimid, Bortezomib, Velcade
University of Arkansas, Janssen, LP
Multiple Myeloma
10/24
10/25
NCT04140162: Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Active, not recruiting
2
57
US
Daratumumab, Lenalidomide, Bortezomib, Dexamethasone
University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC
Multiple Myeloma
08/24
08/26
NCT06140966: Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Recruiting
2
54
RoW
Daratumumab, Darzalex, Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone, Baycadron, Cisplatin, Platinol, epirubicin, Pharmorubicin, Cyclophosphamide, Cytoxan, Etoposide, Eposin, Melphalan, Alkeran, ASCT, autologous stem cell transplantation, bortezomib, Velcade
Wuhan Union Hospital, China
Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma
10/26
10/27
ASCENT, NCT03289299: Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Active, not recruiting
2
87
US
Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone
International Myeloma Foundation, Amgen, Janssen Scientific Affairs, LLC, Celgene, Trevie, Inc.
Smoldering Multiple Myeloma
09/23
11/31
NCT04304144: A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

Completed
2
25
US
CAEL-101, Anselamimab, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab
Alexion Pharmaceuticals, Inc.
AL Amyloidosis
11/23
11/23
NCT06158269: DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

Recruiting
2
40
RoW
DVRd
Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
12/26
12/27
CheckMate 142, NCT02060188 / 2013-003939-30: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

Checkmark Data from CheckMate142 trial of nivolumab/Ipilimumab combination in 1L MSI-H or dMMR mCRC
Aug 2022 - Aug 2022: Data from CheckMate142 trial of nivolumab/Ipilimumab combination in 1L MSI-H or dMMR mCRC
Hourglass Dec 2018 - Dec 2018 : Completion of P2 study of BMS-986016 + nivolumab for metastatic CRC
Checkmark In previously untreated patients with MSI-H or dMMR mCRC
Oct 2018 - Oct 2018: In previously untreated patients with MSI-H or dMMR mCRC
More
Active, not recruiting
2
385
Europe, Canada, US, RoW
Ipilimumab, Yervoy, Nivolumab, BMS-936558, Opdivo, Cobimetinib, Cotellic, Daratumumab, Darzalex, BMS-986016
Bristol-Myers Squibb
Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
09/24
09/24
DART, NCT04703621 / 2019-004683-22: The Study- Daratumumab Treatment in ITP

Active, not recruiting
2
21
Europe
Daratumumab Injection, Darzalex
Ostfold Hospital Trust, Haukeland University Hospital, Oslo University Hospital, University Hospital, Akershus, Henri Mondor University Hospital, Odense University Hospital
ITP
04/24
12/24
NCT04661137: A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Recruiting
2
96
US
Selinexor 60 MG, KPT-330, Selinexor 80 MG, Selinexor 100 MG, Carfilzomib, Kyprolis, Pomalidomide, Pomalyst, Daratumumab, Darzalex, Dexamethasone, Dextenza, Ozurdex, Neofordex, others
Hackensack Meridian Health, Karyopharm Therapeutics Inc
Multiple Myeloma
01/25
01/25
IFM2018-01, NCT03669445: Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma

Recruiting
2
45
Europe
Ixazomib, Lenalidomide, Dexamethasone, Daratumumab
University Hospital, Toulouse
Multiple Myeloma
03/24
12/24
NCT05704400: Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome

Recruiting
2
20
Europe
Rituximab Biosimilar ABP 798, Daratumumab
Istituto Giannina Gaslini
Nephrotic Syndrome
03/24
03/25
SUN-RAY, NCT06358638: Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY

Recruiting
2
12
US
Daratumumab, Darzalex, Alemtuzumab, Campath-1H, Sirolimus, Rapamune, Total Body Irradiation, TBI
Children's National Research Institute, Alberta Children's Hospital, The Hospital for Sick Children, Levine Children's Hospital, Ann & Robert H Lurie Children's Hospital of Chicago, Nationwide Children's Hospital, Children's Hospital at Montefiore, Doris Duke Charitable Foundation, Janssen Pharmaceuticals
Sickle Cell Disease
09/44
09/54
IFm2022-01, NCT06353022: Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

Not yet recruiting
2
103
Europe
Teclistamab, No more information, Talquetamab, Lenalidomide, Bortezomib, Daratumumab, Dexamethasone
Nantes University Hospital, Janssen Pharmaceutica
Multiple Myeloma
04/26
06/30
NCT04352205: Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Terminated
2
17
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Thalidomide, (+)-Thalidomide, (-)-Thalidomide, .alpha.-Phthalimidoglutarimide, 2, 6-Dioxo-3-phthalimidopiperidine, Alpha-Phthalimidoglutarimide, Contergan, Distaval, Kevadon, N-(2,6-Dioxo-3-piperidyl)phthalimide, N-Phthaloylglutamimide, N-Phthalylglutamic Acid Imide, Neurosedyn, Pantosediv, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-, Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-, Sedalis, Sedoval K-17, Softenon, Synovir, Talimol, Thalomid
Emory University, Janssen Scientific Affairs, LLC, National Cancer Institute (NCI)
Plasma Cell Myeloma, Renal Failure
01/24
01/24
NCT03012880: Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed
2
80
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Questionnaire Administration
Mayo Clinic, National Cancer Institute (NCI)
Plasma Cell Myeloma
04/22
07/22
NCT03896737 / 2018-002089-37: Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Active, not recruiting
2
401
Europe, RoW
Daratumumab plus Velcade Cyclophosphamide Dexamethasone, Velcade Thalidomide Dexamethasone
Stichting European Myeloma Network, EMN Trial Office S.r.l. Impresa Sociale
Multiple Myeloma
06/25
02/26
NCT04176718: Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Recruiting
2
43
US
Daratumumab, Darzalex, Carfilzomib, Kyprolis, Pomalidomide, Pomalyst, Imnovid, Dexamethasone, Dexasone, Diodex, hexadrol
Andrew Yee, MD, Amgen, Janssen Research & Development, LLC
Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
05/25
05/26
IDA53, NCT03734198: Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

Active, not recruiting
2
29
Europe
Ibrutinib, Ibrutinib treatment, Daratumumab, Daratumumab perfusion
French Innovative Leukemia Organisation, Janssen, LP
Relapsed or Refractory Chronic Lymphocytic Leukemia
06/24
06/26
NCT06418477: Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD

Recruiting
2
20
RoW
Dara-CyBorD
Peking University People's Hospital
Monoclonal Gammopathy of Renal Significance
12/25
12/26
TALTEC, NCT06505369: Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

Recruiting
2
50
Europe
Daratumumab, JNJ-54767414, Bortezomib, EU Substance number SUB20020, Lenalidomide, EU Substance number SUB25389, Dexamethasone, EU Substance number SUB07017MIG, Talquetamab, JNJ-64407564, Teclistamab, JNJ-64007957
North Estonia Medical Centre, Janssen Pharmaceutica
Multiple Myeloma
11/26
10/28
NCT03556332: A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

Active, not recruiting
2
41
US
Carfilzomib, Lenalidomide, Dexamethasone, Daratumumab, autologous hematopoietic cell transplantation
Memorial Sloan Kettering Cancer Center, Janssen Pharmaceuticals
Multiple Myeloma
07/25
07/25
DEDALO, NCT04124497: A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients

Active, not recruiting
2
45
Europe
Daratumumab, Darzalex, Pomalidomide, Imnovid, Dexamethasone
Fondazione EMN Italy Onlus
Multiple Myeloma, Deletion 17P Syndrome
07/25
07/25
DARALLO, NCT04024384: Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial

Withdrawn
2
0
Europe
Daratumumab
Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
07/24
07/24
 

Download Options